An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases

E-ISSN： 2212-3938|7|4|271-275

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.7, Iss.4, 2012-11, pp. : 271-275

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

By Kalliolias George D C Liossis Stamatis-Nick

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 349-359

Informa Healthcare

Access to resources Recommend Favorite

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2141-2144

Informa Healthcare

Access to resources Recommend Favorite

Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure

By Slawsky Mara T Givertz Michael M

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 2, 2009-02 ,pp. : 311-322

Informa Healthcare

Access to resources Recommend Favorite

Finding a Place for Interleukin-1 Inhibitors in the Treatment of Rheumatologic Diseases

Current Pharmaceutical Design, Vol. 21, Iss. 17, 2015-05 ,pp. : 2198-2205

Bentham Science Publishers

Access to resources Recommend Favorite

Co-Expression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist Improves Human Islet Survival and Function

By Narang Ajit Sabek Omaima Gaber Ahmed Mahato Ram

Pharmaceutical Research, Vol. 23, Iss. 9, 2006-09 ,pp. : 1970-1982

Springer Publishing Company

Access to resources Recommend Favorite